TABLE 3.
Management of a male versus female patient with COPD
| Male patient | Female patient | p-value | |
| Cases n | 62 | 72 | |
| Short-acting bronchodilator | 62 (100) | 72 (100) | >0.999 |
| Long-acting anti-cholinergic inhaler | 62 (100) | 72 (100) | >0.999 |
| Long-acting β2-agonist inhaler | 14 (23) | 27 (38) | 0.062 |
| Both long-acting anti-cholinergic and β2-agonist inhalers | 32 (52) | 40 (56) | 0.648 |
| ICS | 14 (23) | 17 (24) | 0.888 |
| Triple therapy | 19 (31) | 26 (36) | 0.504 |
| OCS | 10 (16) | 9 (13) | 0.548 |
| Respiratory rehabilitation treatment | 46 (74) | 54 (75) | 0.915 |
| Consultation with a dietitian | 45 (73) | 48 (67) | 0.459 |
| Oxygen therapy | 0 (0) | 0 (0) | 1.0 |
| Changing the inhaler# | 4 (6) | 5 (7) | 0.910 |
| Intensifying respiratory rehabilitation treatment# | 4 (6) | 12 (17) | 0.069 |
| Benzodiazepines# | 1 (2) | 0 (0) | 0.279 |
| Opioids# | 6 (10) | 9 (13) | 0.605 |
| Oral steroids# | 5 (8) | 3 (4) | 0.342 |
| Roflumilast (Daxas)# | 4 (6) | 2 (3) | 0.305 |
| Oxygen therapy# | 2 (3) | 0 (0) | 0.125 |
Data are presented as n (%), unless otherwise stated. ICS: inhaled corticosteroids; OCS: oral corticosteroids. #: follow-up management.